Showing 2711-2720 of 7413 results for "".
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- Mohs Surgery as Effective as Wide Excision for Lentigo Maligna Melanoma: Studyhttps://practicaldermatology.com/news/mohs-surgery-effective-wide-excision-lentigo-maligna-melanoma-study/2468603/New research suggests Mohs micrographic surgery (MMS) may be as effective as wide local excision (WLE) in treating lentigo maligna (LM) and lentigo maligna melanoma (LMM), without compromising melanoma-specific survival rates. Lentigo maligna, often found on sun-damaged skin in older patie
- Zasocitinib Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/study-zasocitinib-effective-moderate-severe-psoriasis/2468601/Results from a recent placebo-controlled trial of zasocitinib showed promise in improving skin clearance for patients with moderate to severe plaque psoriasis. The phase 2b study, conducted across multiple centers in the United States and Canada, included 259 patients treated over 12 week
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro
- AD Drugs Market Predicted to Grow From $10.5 Billion to $24.5 Billionhttps://practicaldermatology.com/news/ad-drugs-market-predicted-grow-105-billion-245-billion/2468511/A new market research report predicts that the global atopic dermatitis (AD) drugs market will grow at a compound annual growth rate of 9.1% from now through 2033, going from $10.5 billion in 2023 to $24.5 billion by 2033. The report, from market.us, is titled, “Atopic Dermatitis Drugs Mar
- 'Me & My Inner Circle' Launches on World Psoriasis Dayhttps://practicaldermatology.com/news/me-my-inner-circle-launches-world-psoriasis-day/2468497/October 29 is World Psoriasis Day, and Almirall recognized the occasion by launching an awareness campaign called “Me & My Inner Circle,” with the support of the International Federation of Psoriasis Associations (IFPA), the company announced. The campaign features Alma, representing a
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini